Sorafenib Metabolism Is Significantly Altered in the Liver Tumor Tissue of Hepatocellular Carcinoma Patient

BACKGROUND: Sorafenib, the drug used as first line treatment for hepatocellular carcinoma (HCC), is metabolized by cytochrome P450 (CYP) 3A4-mediated oxidation and uridine diphosphate glucuronosyl transferase (UGT) 1A9-mediated glucuronidation. Liver diseases are associated with reduced CYP and UGT...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Ling, Yang, Xiaoshan, Guo, Enshuang, Chen, Weiying, Lu, Linlin, Wang, Ying, Peng, Xiaojuan, Yan, Tongmeng, Zhou, Fuyan, Liu, Zhongqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010532/
https://www.ncbi.nlm.nih.gov/pubmed/24797816
http://dx.doi.org/10.1371/journal.pone.0096664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010532/
https://www.ncbi.nlm.nih.gov/pubmed/24797816
http://dx.doi.org/10.1371/journal.pone.0096664

Ejemplares similares